Birdshot Chorioretinopathy
Birdshot chorioretinopathy (BSCR; MIM605808) is a rare, chronic autoimmune inflammatory condition affecting the eye, specifically a form of posterior uveitis. [1] It is characterized by severe, progressive inflammation within the eye, typically in the posterior segment, which often leads to extensive retinal atrophy and, ultimately, blindness. [1] This debilitating disease primarily affects middle-aged and elderly individuals of European descent, with a slight female predominance. [1]
Biological Basis
BSCR exhibits a remarkably strong genetic association with the human leukocyte antigen (HLA) system, with over 95% of affected individuals carrying the HLA-A29 allele. [1] Specifically, the HLA-A*29:02 allele is identified as the principal MHC association. [1] Despite the high prevalence of HLA-A29 in European populations, only a small subset of individuals carrying this allele develops BSCR, suggesting that other genetic and environmental factors are involved in disease development. [1]
Recent research has identified additional susceptibility genes beyond the HLA region. A genome-wide association study (GWAS) revealed a functional haplotype in the ERAP2 gene, located at 5q15, as a significant risk factor for BSCR. [1] The disease-associated variants in this region, such as rs10044354 (which is in high linkage disequilibrium with rs7705093), correlate with altered mRNA and protein expression levels of ERAP2. [1] Individuals homozygous for the C allele of rs10044354 show little to no ERAP2 protein expression, whereas carriers of the T risk allele exhibit higher protein levels. [1] This suggests that differential peptide processing and antigen presentation to T cells, mediated by ERAP2, play a crucial role in the disease mechanism. [1] ERAP2 is known to have distinct peptide trimming capabilities compared to ERAP1, and diseases associated with ERAP1 or ERAP2 often share a major HLA class I association. [1] BSCR is considered an autoimmune disease, sharing characteristics, such as T helper 17-cell responses, with other autoimmune disorders. [1]
Clinical Relevance
The diagnosis of birdshot chorioretinopathy is based on established international consensus criteria. [1] Current treatment strategies involve various immunosuppressive medications aimed at controlling inflammation. However, these treatments frequently fail to prevent or halt the progressive retinal atrophy, highlighting the need for more effective therapeutic interventions. [1]
Social Importance
As a condition that can lead to severe visual impairment and blindness, BSCR has a significant impact on the quality of life for affected individuals. [1] The progressive nature of the disease and the limitations of current treatments underscore the importance of ongoing research to understand its pathogenesis and develop more effective therapies. Patient advocacy groups, such as the Birdshot Uveitis Society, provide support and resources for those living with the condition. [1]
Constraints of Study Design and Statistical Inference
The study involved a relatively small cohort for a genome-wide association study, with 117 birdshot chorioretinopathy cases and 778 controls of European ancestry after quality control. [1] While this cohort size is notable given the rarity of the disease, it inherently limits the statistical power to detect genetic variants with smaller effect sizes, potentially leading to an overestimation of effect sizes for the associations that were identified. [1] The inability to replicate the association with the TECPR2 gene (rs150571175) in an independent British cohort further underscores these statistical limitations, suggesting that some initial findings may not be robust or require larger sample sizes for confirmation. [1]
Generalizability and Phenotypic Nuances
The primary study cohort consisted exclusively of individuals of European descent (Dutch, Spanish, and UK populations), which restricts the generalizability of the findings to other ancestral groups. [1] Genetic susceptibility and disease mechanisms can vary significantly across different ethnicities, meaning the identified ERAP2 haplotype and HLA-A*29:02 association might not hold the same predictive or pathogenic weight in non-European populations. [2] While diagnosis was based on international consensus criteria, the inherent complexity and variable presentation of a rare autoimmune disease like birdshot chorioretinopathy could still introduce subtle phenotypic heterogeneity that is not fully captured or accounted for in the genetic analysis. [3]
Unaccounted Factors and Remaining Knowledge Gaps
The current genome-wide association study primarily focuses on genetic predispositions, acknowledging that "additional exogenous factors are involved in the development of the disease". [1] Critical environmental or lifestyle confounders and potential gene-environment interactions, which are known to play significant roles in complex autoimmune diseases, were not investigated. [1] Despite identifying significant genetic associations, particularly with HLA-A*29:02 and ERAP2, a substantial portion of the disease's heritability likely remains unexplained, as evidenced by the fact that only a small subset of HLA-A29-positive individuals develop birdshot chorioretinopathy. [4] This highlights the need for future research incorporating multi-omics approaches and environmental data to fully elucidate the complex etiology of the disease. [1]
Variants
Birdshot chorioretinopathy (BSCR) is a rare, severe autoimmune eye condition primarily affecting the posterior segment of the eye, often leading to significant visual impairment and retinal atrophy. [1] The disease has a strong genetic component, with over 95% of cases carrying the HLA-A29 allele, but other genetic factors are also involved. [1] Genetic variants in genes like LNPEP and TECPR2 have been investigated for their potential roles in susceptibility to BSCR, influencing immune response and cellular processes critical for retinal health.
The single nucleotide polymorphism (SNP) rs7705093 is located in the region of the LNPEP gene, which encodes for Leucyl/Cystinyl Aminopeptidase, an enzyme involved in degrading various peptides. While rs7705093 itself is not directly detailed for its functional impact, it is in strong linkage disequilibrium (LD) with rs10044354, a variant significantly associated with BSCR risk. [1] This rs10044354 variant functions as an expression quantitative trait locus (eQTL) for the ERAP2 gene, meaning it influences the expression levels of ERAP2. [1] Specifically, carriers of the T risk allele for rs10044354 show higher ERAP2 protein levels, suggesting that altered antigen processing and presentation by ERAP2 contributes to BSCR pathogenesis. [1] Importantly, studies indicate that rs10044354 has no significant impact on the expression of LNPEP itself. [1]
Another variant, rs150571175, is found within the TECPR2 gene, which codes for Tectonin Beta-Propeller Repeat Containing 2. The TECPR2 protein plays a crucial role in autophagy, a cellular process vital for recycling damaged cell components and maintaining cellular health, by interacting with Atg8 orthologs and promoting autophagosome accumulation. [1] A significant association between rs150571175 and birdshot chorioretinopathy was observed in Dutch and Spanish populations. [1] However, this association could not be consistently replicated in a British cohort, indicating a need for further research across diverse populations to clarify its precise contribution to BSCR. [1] Autophagy is particularly important for the function and health of photoreceptors in the retina, and dysregulation of autophagy-related genes has been implicated in other autoimmune diseases, suggesting a potential pathway for TECPR2's involvement in BSCR. [1]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs150571175 | TECPR2 | birdshot chorioretinopathy |
| rs7705093 | LNPEP | birdshot chorioretinopathy |
Ocular Manifestations and Disease Progression
Birdshot chorioretinopathy is characterized by severe and progressive intraocular inflammation primarily affecting the posterior segment of the eye, which can ultimately lead to profound visual impairment and blindness. [5] The typical clinical presentation involves a chronic inflammatory process that results in extensive retinal atrophy over time stage of birdshot retinochoroidopathy. While specific subjective symptoms are not detailed, the consequence of this progressive inflammation is a decline in visual function, making visual acuity and field assessments critical objective measures to monitor disease severity and progression.
Genetic and Immunological Markers
A hallmark of birdshot chorioretinopathy is its exceptionally strong association with the HLA-A29 allele, with over 95% of diagnosed cases carrying this genetic marker, specifically the HLA-A*29:02 allele . [2], [6], [7] Diagnostic approaches thus heavily rely on HLA typing to identify the presence of HLA-A29, which serves as a crucial diagnostic criterion. Furthermore, research indicates that variants near the ERAP2 gene at 5q15 are associated with a predisposition to birdshot chorioretinopathy, with these variants correlating to mRNA and protein expression levels of ERAP2, suggesting a role for differential peptide processing and antigen presentation to T cells in the disease mechanism. [1] Intraocular levels of interleukin-17 and other proinflammatory cytokines have also been identified, indicating their involvement as potential biomarkers in the inflammatory process. [8]
Demographic Patterns and Diagnostic Considerations
Birdshot chorioretinopathy is predominantly observed in middle-aged and elderly individuals of European descent, exhibiting a slight female predominance . [2], [4] Despite the high prevalence of the HLA-A29 allele in European populations, only a small fraction of individuals carrying this allele develop the condition, highlighting the role of additional genetic and exogenous factors in its pathogenesis. [1] Diagnosis is guided by international consensus criteria [3] which integrate clinical signs, symptoms, and the presence of the HLA-A29 allele to differentiate birdshot chorioretinopathy from other forms of uveitis. The progressive nature of the disease and the ineffectiveness of current immunosuppressive treatments in preventing retinal atrophy underscore the importance of early diagnosis and the search for more effective therapeutic strategies. [1]
Genetic Susceptibility and Antigen Presentation
Birdshot chorioretinopathy (BSCR) is profoundly linked to specific genetic variations within the human leukocyte antigen (HLA) system, particularly the HLA-A29 allele. Over 95% of individuals diagnosed with BSCR carry HLA-A29, making it the strongest known HLA association for a human disease. [1] Further fine-mapping has identified HLA-A*29:02 as the principal associated allele, demonstrating an exceptionally high odds ratio for disease development. [1] This strong association suggests a critical role in immune system regulation, specifically in the presentation of antigenic peptides to T cells, which is a hallmark of autoimmune conditions.
Beyond the major histocompatibility complex, a novel susceptibility locus has been identified near the ERAP2 gene on chromosome 5q15. [1] The risk allele for this polymorphism is associated with higher mRNA and protein expression levels of ERAP2 in B cells. [1] ERAP2 encodes an endoplasmic reticulum aminopeptidase that, along with ERAP1, is involved in trimming peptides to optimal lengths for presentation by MHC class I molecules like HLA-A29. [1] This differential peptide processing and antigen presentation to T cells is considered an essential mechanism in BSCR pathogenesis, suggesting that genetic variants affecting ERAP2 function can influence the immune response in a way that contributes to the disease.
Broader Genetic Landscape and Autoimmune Links
The genetic architecture of BSCR extends beyond the primary HLA-A29 association, encompassing other potential risk loci and overlaps with the genetic predispositions of other autoimmune diseases. A genome-wide association study also identified an association with the TECPR2 gene on chromosome 14q32.31. [1] While this specific association required further confirmation, TECPR2 is known to play a role in autophagy, a cellular process crucial for the health and function of retinal photoreceptors. [1] Dysregulation of autophagy-related genes has been implicated in other autoimmune conditions, suggesting a potential shared pathway in BSCR.
Given that BSCR is recognized as an autoimmune disease, it is hypothesized to share genetic risk factors with other autoimmune disorders that exhibit similar T helper 17-cell responses. [1] Studies have investigated the cumulative effect of genetic variants associated with diseases such as ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, vitiligo, type 1 diabetes, and multiple sclerosis. [1] This broader genetic context implies a polygenic risk component where multiple genes, each contributing a small effect, collectively increase susceptibility to BSCR.
Demographic and Environmental Modulators
While genetic factors are paramount, demographic characteristics and environmental influences also play a role in the manifestation of birdshot chorioretinopathy. The disease predominantly affects middle-aged and elderly individuals, indicating an age-related component to its onset. [1] Furthermore, there is a slight female predominance observed in BSCR cases. [1] The majority of individuals diagnosed with BSCR are of European descent, which aligns with the prevalence of the HLA-A29 allele in these populations. [1]
Although specific environmental triggers are not explicitly detailed, it is understood that additional "exogenous factors" are involved in disease development, alongside genetic predispositions. [1] These might encompass a range of external elements, such as specific infections, dietary components, or other lifestyle exposures, which could interact with an individual's genetic makeup to initiate or exacerbate the autoimmune response characteristic of BSCR. However, the precise nature of these environmental factors remains an area for further investigation.
Gene-Environment Interplay
The development of birdshot chorioretinopathy is not solely determined by genetic inheritance but also involves complex interactions between an individual's genetic predisposition and various environmental elements. Despite the extremely strong association with HLA-A29, only a small fraction of HLA-A29-positive individuals develop the disease. [1] This observation strongly implies that genetic susceptibility requires interaction with other factors, presumably exogenous or environmental, to trigger the autoimmune cascade leading to BSCR. [1] For instance, specific environmental triggers could initiate an immune response in genetically susceptible individuals, leading to the breakdown of ocular immune tolerance.
The interplay between genes like HLA-A29 and ERAP2, which are critical for antigen processing and presentation, and unidentified environmental stimuli is crucial. Such interactions could lead to the erroneous presentation of self-peptides, or the aberrant processing of foreign peptides that mimic ocular self-antigens, thereby driving the autoimmune inflammation seen in BSCR. While the exact environmental triggers and their specific mechanisms of interaction with genetic factors are yet to be fully elucidated, their role in disease penetrance and progression is considered significant.
Biological Background
Birdshot chorioretinopathy (BSCR) is a rare, severe autoimmune disorder affecting the posterior segment of the eye, characterized by progressive intraocular inflammation that can lead to extensive retinal atrophy and blindness. [2] The condition predominantly affects middle-aged and elderly individuals of European descent, with a slight female predisposition. [2] Understanding the intricate biological mechanisms underlying BSCR is crucial for developing effective treatments, as current immunosuppressive strategies often fail to halt the progression of retinal damage. [1]
Genetic Predisposition and Immune Recognition
A pivotal genetic factor in birdshot chorioretinopathy is its exceptionally strong association with the human leukocyte antigen (HLA) system, specifically with the HLA-A29 allele, which is present in over 95% of individuals with BSCR. [6] Among these, the HLA-A*29:02 allele is the primary MHC signal linked to the condition. [1] While HLA-A29 is relatively common in European populations, only a small fraction of HLA-A29-positive individuals develop BSCR, indicating that other genetic and environmental factors are also involved in disease susceptibility. [4] This strong HLA association points to a critical role for antigen presentation and T-cell mediated immune responses in the disease pathogenesis.
Recent research has identified variants near the ERAP2 gene on chromosome 5q15 as predisposing factors for BSCR. [1] These disease-associated genetic variations correlate with altered messenger RNA (mRNA) and protein expression levels of ERAP2. [1] The ERAP2 gene undergoes balancing selection, maintaining two main haplotypes (A and B) that result in differential protein expression due to alternative mRNA splicing. [1] Individuals with BSCR tend to exhibit high expression levels of ERAP2, contrasting with low or absent expression in homozygous negative healthy individuals, suggesting that ERAP2 plays a specific role in generating or destroying immunodominant peptides recognized by HLA-A29 in the context of BSCR. [1]
Molecular Pathways of Antigen Processing
ERAP2 (Endoplasmic Reticulum Aminopeptidase 2) is a key biomolecule involved in the major histocompatibility complex (MHC) class I antigen presentation pathway. [9] Within the endoplasmic reticulum, ERAP2 functions as an aminopeptidase, trimming peptides to the optimal length for binding to MHC class I molecules like HLA-A29. [9] This process is crucial for presenting intracellular antigens to cytotoxic T lymphocytes, initiating an immune response. [9] Differential peptide processing and antigen presentation to T cells, influenced by ERAP2 expression, are considered essential disease mechanisms for BSCR. [1]
ERAP2 works in concert with ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) in peptide trimming, though they possess nonoverlapping capacities. [10] The interaction between ERAP genes and HLA class I genes has been implicated in the immunopathology of several autoimmune diseases, such as ankylosing spondylitis and psoriasis. [11] This suggests a broader mechanism where variations in ERAP function, in conjunction with specific HLA alleles, lead to the presentation of aberrant or self-peptides that trigger autoimmune responses. [11] Modulating this peptide processing pathway by targeting ERAP2 may offer therapeutic potential for BSCR. [1]
Cellular Inflammation and Tissue Damage in the Eye
Birdshot chorioretinopathy is characterized by severe intraocular inflammation, primarily affecting the posterior segment of the eye, including the retina and choroid. [2] This chronic inflammatory state leads to the progressive destruction of retinal tissue and eventual blindness. [12] Key cytokines, such as interleukin-17 and other pro-inflammatory cytokines, are found at elevated levels within the eyes of individuals with HLA-A29-associated BSCR. [1] Other cytokines like interleukin-21, interleukin-23, and transforming growth factor beta1 (TGFβ1) have also been implicated in the disease pathogenesis. [13]
The sustained immune attack results in extensive retinal atrophy, which is a hallmark of advanced BSCR. [2] This tissue damage underscores the failure of homeostatic mechanisms within the eye to control inflammation and protect delicate neural structures. The specific targeting of the retina and choroid suggests that certain retinal antigens, when improperly processed and presented by HLA-A29 in the context of altered ERAP2 function, become targets for autoreactive T cells, driving the chronic inflammatory process. [1]
Autophagy and Retinal Homeostasis
The gene TECPR2 (tectonin beta-propeller repeat-containing 2) has also been investigated in BSCR, though its association requires further replication across diverse populations. [1] TECPR2 is known to interact with Atg8 orthologs and acts as a positive regulator of autophagy, a fundamental cellular process involving the degradation and recycling of cellular components. [14] Autophagy is crucial for maintaining cellular health and homeostasis, particularly in highly metabolic tissues like the retina. [15] The eye maintains a unique form of autophagy essential for the function and health of photoreceptors, the light-sensing cells in the retina. [15]
Disruptions in autophagy can have significant consequences for retinal health. Studies have shown that modulating autophagy with agents like rapamycin can paradoxically either reduce or exacerbate uveitis, highlighting the complex role of this pathway in ocular inflammation. [16] Furthermore, autophagy-related genes have been associated with other autoimmune conditions, including systemic lupus erythematosus and Crohn’s disease. [17] The potential involvement of TECPR2 and autophagy pathways in BSCR suggests that defects in cellular waste removal and quality control mechanisms might contribute to the disease’s pathophysiology and progression of retinal damage. [1]
Antigen Processing and Presentation Dysregulation
Birdshot chorioretinopathy is strongly associated with the HLA-A29 allele, particularly HLA-A*29:02, which is present in over 95% of cases. [1] This robust genetic link suggests a central role for the major histocompatibility complex (MHC) class I pathway in disease pathogenesis. The HLA-A29 molecule is critical for presenting antigenic peptides to T cells, thereby initiating an immune response against specific targets within the eye. [5]
Further mechanistic insights point to the involvement of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2), an enzyme crucial for trimming peptides to the optimal length for HLA class I binding. Genetic variants near the ERAP2 gene at locus 5q15 are significantly associated with birdshot chorioretinopathy, impacting both mRNA and protein expression levels of ERAP2. [1] ERAP2 works in concert with ERAP1 within the endoplasmic reticulum to refine the peptide repertoire presented on HLA molecules, and its differential activity, potentially due to specific haplotypes, is hypothesized to lead to the generation or destruction of immunodominant epitopes capable of binding to HLA-A29. [10] This dysregulation in peptide processing and antigen presentation is considered a fundamental mechanism driving the T-cell mediated autoimmune response characteristic of the disease. [1]
Immune Signaling and Inflammatory Pathways
The autoimmune nature of birdshot chorioretinopathy is underscored by the presence of significant intraocular inflammation, involving complex signaling cascades and cytokine networks. Studies have identified elevated levels of pro-inflammatory cytokines, including interleukin-17 (IL-17), within the eyes of individuals with HLA-A29-associated birdshot chorioretinopathy. [8] IL-17 is a key cytokine in inflammatory and autoimmune diseases, often mediating tissue damage and contributing to the perpetuation of the immune response.
Other cytokines, such as interleukin 21 (IL-21), interleukin 23 (IL-23), and transforming growth factor beta1 (TGF-beta1), are also implicated in the pathogenesis of birdshot chorioretinopathy. [13] These cytokines regulate the differentiation and function of various immune cells, particularly T helper cell subsets, which orchestrate the inflammatory processes in the posterior eye segment. The interplay and dysregulation of these cytokine pathways contribute to the chronic and progressive intraocular inflammation observed in the condition, ultimately leading to retinal atrophy and visual impairment. [12]
Autophagy and Retinal Homeostasis
Cellular homeostasis in the retina, particularly for photoreceptor health, relies on a unique form of autophagy. [15] The TECPR2 gene, which encodes a protein involved in autophagy as a positive regulator of autophagosome accumulation and interacts with Atg8 orthologs, has shown an association with birdshot chorioretinopathy in some populations. [14] While this finding requires further replication across diverse cohorts, it suggests a potential link between defects in cellular waste removal and the disease's immunopathology.
Dysregulation of autophagy can have profound effects on cellular function and survival, especially in metabolically active tissues like the retina. Interestingly, pharmacological modulation of autophagy, for instance with rapamycin, has shown paradoxical effects in uveitis models, either reducing or exacerbating the inflammation. [16] This highlights the delicate balance of autophagic pathways in maintaining retinal health and the complexity of targeting this mechanism therapeutically in autoimmune eye conditions. [1]
Genetic Predisposition and Molecular Regulation
The genetic landscape of birdshot chorioretinopathy is dominated by the strong association with HLA-A29, a major HLA class I allele, found in nearly all affected individuals. [1] However, since HLA-A29 is relatively common in the general population, additional genetic and environmental factors are critical for disease manifestation. [4] This indicates a complex interplay where HLA-A29 provides a necessary, but not sufficient, genetic background.
A significant contributing factor is a functional haplotype near the ERAP2 gene, which predisposes individuals to birdshot chorioretinopathy. [1] This disease-associated haplotype correlates with high ERAP2 mRNA and protein expression levels, influencing peptide processing and subsequent antigen presentation. ERAP2 undergoes balancing selection, maintaining haplotypes with highly differential protein expression due to alternative mRNA splicing, and the identified disease-associated variants serve as tags for these functional haplotypes. [1] The cumulative effect of these genetic variations, particularly the combination of HLA-A29 and specific ERAP2 alleles, creates a unique molecular environment that facilitates the autoimmune attack on retinal tissues.
Genetic Susceptibility and Diagnostic Biomarkers
Birdshot chorioretinopathy (BSCR) is profoundly linked to specific genetic markers, offering significant diagnostic utility and avenues for risk assessment. Over 95% of individuals with BSCR carry the HLA-A29 allele, with HLA-A*29:02 identified as the principal MHC association, representing the strongest HLA association documented for any human disease. [1] This exceptionally high prevalence of HLA-A*29:02 makes it a powerful diagnostic biomarker, aiding clinicians in confirming a BSCR diagnosis, especially when integrated with established international consensus criteria. [1]
While HLA-A29 is relatively common in European populations, only a small fraction of carriers develop BSCR, indicating the involvement of additional genetic or environmental factors. [1] The identification of a functional ERAP2 haplotype, marked by rs7705093, which correlates with elevated ERAP2 mRNA and protein expression, provides a critical second genetic layer for risk stratification. [1] This combined genetic profile of HLA-A*29:02 and the ERAP2 risk haplotype can help identify individuals within the HLA-A29 positive population who are at a significantly higher risk of developing BSCR, potentially guiding more targeted monitoring strategies.
Pathophysiological Insights and Therapeutic Avenues
The genetic discoveries in BSCR offer crucial insights into its underlying pathophysiology, which can guide future prognostic assessments and therapeutic development. The strong association of a functional ERAP2 haplotype with increased ERAP2 expression suggests that differential peptide processing and subsequent antigen presentation to T cells are essential mechanisms driving BSCR. [1] This mechanistic understanding is particularly vital given that BSCR is a severe, progressive autoimmune uveitis leading to extensive retinal atrophy and blindness, and current immunosuppressive treatments often fail to halt disease progression. [1]
By unraveling the role of ERAP2 in antigen processing, these findings establish a foundation for developing more targeted therapeutic interventions. Strategies aimed at modulating ERAP2 activity or intervening in the specific antigen presentation pathways could represent personalized medicine approaches. Such targeted treatments hold the promise of more effectively preventing retinal damage, mitigating disease progression, and ultimately improving long-term visual outcomes for patients, thereby addressing the current limitations of broad-spectrum immunosuppression. [1]
Overlapping Autoimmune Pathways
BSCR is classified as an autoimmune disease and exhibits shared immunological signatures, particularly T helper 17-cell responses, with other autoimmune conditions. [1] The genetic association with variants near the ERAP2 gene is highly relevant in this context, as members of the ERAP family, such as ERAP1 and ERAP2, are known to play roles in the pathogenesis of other autoimmune diseases like ankylosing spondylitis and psoriasis through their interactions with HLA alleles. [1] This suggests a common genetic predisposition and shared immunological mechanisms underlying a spectrum of autoimmune disorders, which could inform broader clinical perspectives on comorbidity and patient care.
Furthermore, the study briefly identified an association with the TECPR2 gene, which is involved in autophagy, although this finding required further replication. [1] Autophagy-related genes have also been implicated in other autoimmune diseases such as systemic lupus erythematosus and Crohn's disease. [1] This reinforces the concept of shared genetic and molecular pathways across different autoimmune conditions, potentially guiding comprehensive patient management, risk assessment for co-existing conditions, and facilitating the development of broader therapeutic strategies that target common inflammatory or cellular processes.
Frequently Asked Questions About Birdshot Chorioretinopathy
These questions address the most important and specific aspects of birdshot chorioretinopathy based on current genetic research.
1. My mom has this eye condition. Will I get it too?
While there's a strong genetic association, it's not a simple "yes" or "no." Over 95% of people with this condition carry a specific genetic marker called HLA-A29. However, many individuals with this marker never develop the eye disease, suggesting that other genetic and environmental factors are also involved. It's important to discuss your family history with an eye specialist.
2. I'm not European. Am I still at risk for this eye problem?
The primary research on this condition has focused almost exclusively on individuals of European descent, where it's most commonly observed. This means the specific genetic risk factors identified, like HLA-A29 and ERAP2 variants, might not have the same significance in other ancestral groups. While it's considered rare, it's possible for anyone to develop the condition, so discuss any concerns with your doctor.
3. Why did my eye problems start when I was older, not younger?
This condition primarily affects middle-aged and elderly individuals. While the exact timing of onset isn't fully understood, it's a common characteristic for many autoimmune diseases to manifest later in life. Genetic predispositions, like carrying HLA-A*29:02, often interact with other factors over time to trigger the disease process.
4. Are women more likely to get this eye disease than men?
Yes, studies indicate a slight female predominance for this eye condition. While it can affect both sexes, it is diagnosed somewhat more often in women. This pattern of higher prevalence in females is also observed in many other autoimmune disorders.
5. My vision is getting worse. Can anything stop it?
Current treatments typically involve various immunosuppressive medications aimed at controlling the inflammation. However, these treatments frequently fail to prevent or halt the progressive retinal atrophy that can lead to severe vision loss. Researchers are actively working to find more effective therapeutic interventions to better protect vision.
6. Can a special test tell me if I'm at risk for this eye disease?
Yes, a blood test can check for the HLA-A29 genetic marker, specifically the HLA-A*29:02 allele, which is present in over 95% of individuals with this condition. However, having this marker doesn't guarantee you'll get the disease, as only a small subset of HLA-A29 positive people develop it. It's one piece of information for your doctor.
7. I have another autoimmune disease. Does that mean I'm more likely to get this eye condition?
This eye condition is indeed an autoimmune disease, sharing characteristics like specific T helper 17-cell responses with other autoimmune disorders. While having one autoimmune condition can sometimes increase the risk for others, this particular eye condition is quite rare. You should discuss any concerns about your overall autoimmune risk with your doctor.
8. Is there anything I can do, like diet or exercise, to prevent this eye condition?
While a healthy lifestyle is beneficial for overall well-being, specific environmental or lifestyle factors that could prevent this eye condition are not yet fully understood. Research acknowledges that "additional exogenous factors" are involved beyond genetics. Currently, there isn't any proven diet or exercise regimen to prevent its onset.
9. This eye condition is so rare. Why me, when others don't get it?
It's true that this is a rare condition. While a strong genetic predisposition, such as carrying the HLA-A29 marker, is present in most affected individuals, only a small fraction of people with this marker actually develop the disease. This highlights a complex interplay of multiple genetic factors, like the ERAP2 gene, and environmental triggers unique to each person.
10. How much will this eye condition change my everyday life?
This condition can significantly impact your quality of life because it often leads to severe visual impairment and, ultimately, blindness. The progressive nature of the disease and the limitations of current treatments mean it may require ongoing medical management and adjustments to daily activities. Patient advocacy groups can also provide valuable support and resources.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Kuiper, J.J.W., Van Setten, J., Ripke, S. et al. (2014) A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy. Hum Mol Genet 23, 6729–6737.
[2] Shah, K.H., et al. "Birdshot chorioretinopathy." Survey of Ophthalmology, vol. 50, 2005, pp. 519-541.
[3] Levinson, R.D., Brezin, A., Rothova, A., Accorinti, M. and Holland, G.N. "Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference." American Journal of Ophthalmology, vol. 141, 2006, pp. 102–108.
[4] Wee, R. and Papaliodis, G. "Genetics of birdshot chorioretinopathy." Seminars in Ophthalmology, vol. 23, 2008, pp. 53–57.
[5] Levinson, R.D. and Gonzales, C.R. "Birdshot retinochoroidopathy: immunopathogenesis, evaluation, and treatment." Ophthalmology Clinics of North America, vol. 15, 2002, pp. 343–350.
[6] Nussenblatt, R.B., et al. "Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen." American Journal of Ophthalmology, vol. 94, 1982.
[7] Priem, H.A., et al. "HLA typing in birdshot chorioretinopathy." American Journal of Ophthalmology, vol. 105, 1988, pp. 182–185.
[8] Kuiper, J.J.W., et al. "Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy." American Journal of Ophthalmology, vol. 152, 2011, pp. 102–108.
[9] Evnouchidou, I., Papakyriakou, A. and Stratikos, E. (2009) A new role for Zn(II) aminopeptidases: antigenic peptide generation and destruction. Curr. Pharm. Des. 15, 3656–e63670.
[10] Saveanu, L., Carroll, O., Lindo, V. et al. (2005) Concerted peptide trimming by human ERAP1and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat. Immunol. 6, 689–697.
[11] Evans, D.M., Spencer, C.C., Pointon, J.J. et al. (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 43, 761–767.
[12] Rothova, A. and Van Schooneveld, M.J. "The end stage of birdshot retinochoroidopathy." British Journal of Ophthalmology, vol. 79, 1995, pp. 1058–1059.
[13] Yang, P. and Foster, C.S. (2013) Interleukin 21, interleukin 23, and transforming growth factor beta1 in HLA-A29-associated birdshot retinochoroidopathy. Am. J. Ophthalmol. 156, 400–406.
[14] Oz-Levi, D., Ben-Zeev, B., Ruzzo, E.K. et al. (2012) Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. Am. J. Hum. Genet. 91, 1065–1072.
[15] Kim, J.Y., et al. "Noncanonical autophagy promotes the visual cycle." Cell, vol. 154, 2013, pp. 365–376.
[16] Roberge, F.G., et al. "Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction." Current Eye Research, vol. 12, 1993, pp. 197–203.
[17] Han, J.W., Zheng, H.F., Cui, Y. et al. (2009) Genome-wide association study in a Chinese Han population identifies nine newsusceptibilityloci for systemic lupus erythematosus. Nat. Genet. 41, 1234–e31237.